8-K: Haemonetics Reports Q4 FY26 Results & FY27 Guidance

Haemonetics Corporation announced fourth quarter and fiscal year 2026 financial results, highlighting revenue growth and providing fiscal 2027 guidance.

Summary

• Haemonetics reported fourth quarter fiscal 2026 revenue of $346.4 million, a 4.8% increase year-over-year.
• Full fiscal year 2026 revenue was $1.334 billion, a 2.0% decrease compared to fiscal 2025.
• Fourth quarter adjusted earnings per diluted share were $1.29, up 4.0% year-over-year.
• Full fiscal year 2026 adjusted earnings per diluted share were $4.96.
• Cash flow from operating activities for the fourth quarter was $71 million, and free cash flow was $45 million.
• Full fiscal year 2026 cash flow from operating activities was $293 million, and free cash flow was $210 million.
• The company repurchased $100 million of its common stock in the fourth quarter.
• Fiscal 2027 guidance includes total revenue growth of 4-7% and adjusted operating margin expansion of 50-100 basis points.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong Q4 performance and promising FY27 guidance, but tempered by GAAP losses and a slight full-year revenue decline due to acquisition-related charges.

Positives

• Strong fourth quarter performance driven by core platforms, with outperformance in Plasma and Blood Management Technologies.
• Sequential improvement noted in Interventional Technologies.
• Fourth quarter fiscal 2026 revenue increased by 4.8% to $346.4 million.
• Organic revenue growth of 4.5% in the fourth quarter, and 8.6% excluding CSL impact.
• Adjusted earnings per diluted share increased by 4.0% to $1.29 in the fourth quarter.
• Full fiscal year 2026 adjusted earnings per diluted share of $4.96.
• Fiscal 2027 guidance projects total revenue growth of 4-7% and adjusted operating margin expansion of 50-100 basis points.
• Company completed its four-year long-range plan, building a more diversified, sustainable, and durable business.

Negatives

• Full fiscal year 2026 revenue decreased by 2.0% to $1.334 billion.
• Fourth quarter GAAP net loss of $20.1 million and loss per diluted share of $(0.44).
• Fourth quarter GAAP operating loss of $23.0 million and operating margin of (6.6)%, compared to operating income of $71.3 million in the prior year.
• Fourth quarter gross margin decreased to 57.2% from 58.4% in the prior year, primarily due to a charge for pre-acquisition inventory.
• Fourth quarter cash flow from operating activities decreased by 39.1% to $71 million.
• Fourth quarter free cash flow decreased by 53.1% to $45 million.
• Cash on hand decreased by $61.3 million to $245.4 million, primarily due to acquisition and share repurchases.
• Full fiscal year 2026 net income decreased by 42.0% to $97.3 million.

Risks

• Potential for disruptions caused by cybersecurity events.
• Failure to realize anticipated strategic benefits and opportunities from acquisitions and divestitures.
• Pricing pressures resulting from trends toward healthcare cost containment and industry consolidation.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Regulatory uncertainties, including receipt or timing of regulatory approvals.
• Indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes.
• Ability to protect intellectual property.
• Litigation and the impact of share repurchases on stock price and volatility.

Future Outlook

For fiscal year 2027, Haemonetics anticipates total reported revenue growth of 4-7%, with organic revenue growth projected at 3-6%. The company expects adjusted operating margin to expand by 50-100 basis points year-over-year and adjusted earnings per diluted share to grow comparably to revenue growth. Free cash flow conversion is targeted at approximately 80% of adjusted net income.

Management Comments

• "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies."
• "We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals."
• "With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."

Industry Context

StockSavvy.ai notes that Haemonetics' results reflect ongoing trends in the medical technology sector, particularly the demand for solutions that improve healthcare efficiency and patient outcomes. The company's focus on core platforms and strategic acquisitions like Vivasure aligns with industry consolidation and innovation drivers.

Comparison to Industry Standards

• The reported 4.8% year-over-year revenue growth in the fourth quarter is a positive indicator, though the full fiscal year revenue decline of 2.0% suggests a challenging year. Industry benchmarks for medical device companies vary, but consistent revenue growth is generally expected.
• The adjusted EPS growth of 4.0% in Q4 is a positive sign of operational efficiency, but the GAAP net loss indicates significant one-time charges impacting reported profitability.
• Free cash flow generation of $210 million for the full year is substantial, demonstrating the company's ability to convert earnings into cash, a key metric for investors.
• The fiscal 2027 guidance for 4-7% revenue growth and margin expansion suggests a return to a growth trajectory, which is in line with expectations for companies in the medical technology space seeking to capitalize on post-pandemic recovery and innovation.

Stakeholder Impact

• Shareholders: The company repurchased $100 million in stock during Q4, potentially increasing shareholder value. The FY27 guidance suggests future growth, which could positively impact stock price.
• Employees: The mention of performance-based compensation and growth investments suggests continued focus on employee incentives and development.
• Creditors: The company's debt levels and cash flow from operations will be closely monitored by creditors, especially given the acquisition-related charges impacting GAAP results.

Next Steps

• Host conference call with investors and analysts on May 7, 2026, at 8:00 a.m. ET to discuss results.
• Continue execution of the strengthened competitive position and focus on disciplined execution for fiscal 2027 and beyond.
• Utilize remaining $325.0 million authorization for share repurchases.

Key Dates

Recommendation

The company shows signs of recovery and strategic progress with strong Q4 results and positive FY27 guidance. However, the GAAP net loss due to acquisition-related charges and the slight full-year revenue decline warrant a cautious 'hold' stance until the impact of these charges is fully absorbed and the growth trajectory is more firmly established.

Keywords

Haemonetics, 8-K, Financial Results, Q4 Earnings, Fiscal 2026, Fiscal 2027 Guidance, Medical Technology, Revenue Growth